
|Articles|March 15, 2003
Intravitreal adjunct may improve outcomes of PDT
New York-Intravitreal triamcinolone acetonide appears to be a useful adjunct to photodynamic therapy (PDT) with verteporfin (Visudyne, Novartis) in the treatment of eyes with choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD), said Richard F. Spaide, MD, at the Macula 2003 meeting here.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Glaukos receives FDA approval for Epioxa topical therapy for keratoconus
2
AAO 2025: Kenneth C. Fan, MD, sees vision gains with MCO-010 in Stargardt disease
3
AAO 2025: Understanding and diagnosing endophthalmitis
4
AAO 2025: Diana Do reviews the real-world use of aflibercept 8 mg
5